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ABSTRACT
Aim: To evaluate the efficacy and safety of replacing
latanoprost with another prostaglandin analogue (PGA) in
patients with glaucoma or ocular hypertension requiring
additional intraocular pressure (IOP) lowering while on
latanoprost.
Methods: Prospective, randomised, investigator-masked,
multicentre clinical trial. Patients on latanoprost 0.005%
monotherapy requiring additional IOP lowering discon-
tinued latanoprost and were randomised to bimatoprost
0.03% (n=131) or travoprost 0.004% (n=135). IOP
was measured at latanoprost-treated baseline and after
1 month and 3 months of replacement therapy.
Results: Baseline mean diurnal IOP on latanoprost was
similar between groups. The mean diurnal IOP was
significantly lower with bimatoprost than with travoprost
at 1 month (p=0.009) and 3 months (p=0.024).
Overall, 22.0% of bimatoprost patients versus 12.1% of
travoprost patients achieved a >15% reduction in diurnal
IOP from latanoprost-treated baseline at both months 1
and 3 (p=0.033). At month 3, the additional mean
diurnal IOP reduction from latanoprost-treated baseline
was 2.1 (95% CI 1.7 to 2.5) mm Hg (11.0%) with
bimatoprost and 1.4 (95% CI 0.9 to 1.8) mm Hg (7.4%)
with travoprost (p=0.024). At 3 months, 11.5% of
bimatoprost and 16.5% of travoprost patients demon-
strated a >1-grade increase in physician-graded con-
junctival hyperaemia (p=0.288). Hyperaemia was
reported as a treatment-related adverse event in 3.1% of
bimatoprost and 1.5% of travoprost patients (p=0.445).
Conclusion: Patients on latanoprost requiring lower IOP
achieved a greater additional short-term diurnal IOP
reduction when latanoprost was replaced by bimatoprost
compared with travoprost. Low rates of hyperaemia were
observed in patients treated with bimatoprost or
travoprost after switching from latanoprost.
A primary goal of medical therapy in glaucoma is
to reduce intraocular pressure (IOP). The once-
daily prostaglandin analogues (PGAs; bimatoprost,
latanoprost and travoprost) typically provide sig-
nificant reductions in IOP
1–4 and have become the
most commonly used first-line agents in glaucoma
and ocular hypertension (OHT).
5 In achieving and
maintaining a target IOP, monotherapy is typically
preferred over the use of multiple IOP-lowering
medications to ensure better compliance and
minimise the risk of topical and systemic adverse
effects.
Patients on a particular PGA who require
additional IOP lowering may achieve further IOP
reduction when switched to a different topical
medication within the PGA class. Data from
parallel-group, randomised clinical trials suggest
that bimatoprost and possibly travoprost may
reduce IOP more effectively than latanoprost,
3 6–9
with a difference in efficacy between latanoprost
and travoprost apparent in late-afternoon IOP
measurements.
39 In patients who are poorly
responsive or non-responsive to latanoprost ther-
apy, bimatoprost has been demonstrated to pro-
vide significant IOP lowering.
10
Studies have demonstrated that even patients
who respond to latanoprost therapy may achieve
additional IOP lowering upon changing therapy to
another PGA.
11–14 Increased efficacy was observed
on a population level when patients in a managed
care plan were systematically switched from
latanoprost to bimatoprost therapy following
changes in the HMO’s pharmacy formulary.
11 In
contrast, the mean IOP of 84 patients system-
atically switched from latanoprost to travoprost in
a prospective study was unchanged up to
3 months after the switch to travoprost.
15 Open-
label studies have shown significant additional
mean IOP lowering of 3.5 mm Hg or 3.2 mm Hg
when latanoprost was replaced by bimatoprost
12 or
travoprost,
13 14 respectively.
Regardless of the IOP-lowering response to
latanoprost, the literature suggests that patients
who fail to achieve sufficiently low IOP on
latanoprost may obtain additional IOP lowering
when switched to another PGA. The purpose of
the present study was to evaluate the efficacy and
tolerability of replacing latanoprost monotherapy
with either bimatoprost or travoprost monother-
apy when IOP was not sufficiently reduced by
latanoprost alone.
METHODS
This randomised, multicentre, investigator-
masked, parallel-group clinical study compared
bimatoprost 0.03% with travoprost 0.004% as
replacement therapy for patients on latanoprost
who required additional IOP lowering. The study
was approved by the Institutional Review Board at
each of the 17 sites and was carried out in
accordance with HIPAA regulations. All patients
who participated in the study provided written
informed consent. The study was registered on the
clinicaltrials.gov website with the identifier
NCT00440011.
Clinical science
74 Br J Ophthalmol 2010;94:74–79. doi:10.1136/bjo.2009.158071The study enrolled adult patients diagnosed as having
glaucoma or OHT in each eye who in the judgement of the
investigator had inadequate IOP control after at least 30 days
on latanoprost monotherapy. Patients were also required to
have best-corrected visual acuity equivalent to a Snellen score of
20/100 or better in each eye. Primary exclusion criteria included
previous inadequate IOP response to bimatoprost or travoprost,
known hypersensitivity or contraindication to any component
of the study medications, active intraocular inflammation or
macular oedema that might be exacerbated by study treatment,
and intraocular or corneal refractive surgery within 3 months
prior to study entry.
After a screening visit, eligible patients were continued on
latanoprost monotherapy for an additional 2 weeks until the
baseline visit (day 0). At baseline, patients discontinued
latanoprost and were randomised 1:1 to monotherapy with
either bimatoprost 0.03% (Lumigan, Allergan, Irvine, California)
or travoprost 0.004% (Travatan, Alcon Laboratories, Fort
Worth, Texas). The randomisation code was computer-gener-
ated, and treatment assignments were unavailable to the
investigators during the study. To maintain investigator
masking, bottles of the study drugs were provided to patients
in identically appearing masked cartons labelled with the
patient randomisation number, and patients were instructed
not to disclose the study medication to the investigator or office
staff. Patients were instructed to instill one drop of the study
medication in each eye once daily in the evening and were
scheduled for follow-up visits at months 1 and 3.
The primaryefficacy outcome measuresweremeanIOP ateach
time point and mean diurnal IOP. IOP was measured using a
calibrated Goldmann applanation tonometer at 09:00 and 16:00
(¡1 h) at the baseline, month 1 and month 3 visits. For each eye,
the average of two consecutive measurements was recorded.
Safety outcome measures included ocular signs on slit-lamp
biomicroscopy, adverse events and visual acuity. Biomicroscopic
findings were scored on a four-grade scale of none to trace (0 to
0.5), mild (1), moderate (2) and severe (3). An adverse event was
defined as any new condition, worsening of a pre-existing
condition or recurrence of a condition that had resolved after
the baseline visit. All adverse events observed by the investi-
gator or reported by patients at the month 1 and month 3 study
visits were recorded, and their severity and potential relation-
ship to study treatment were documented.
The preplanned analyses of IOP were based on the worse eye
(the eye with the higher IOP at 09:00 on baseline) for the intent-
to-treat patient population (all randomised patients) with no
imputation for missing values and used analysis of variance
(ANOVA) to test baseline differences between treatment groups
and analysis of covariance (ANCOVA) with baseline IOP as the
covariate to test differences between treatment groups at
follow-up. The parameters evaluated were mean IOP at each
hour, mean diurnal IOP at each visit, and mean change from
baseline diurnal IOP and IOP at each hour. Diurnal IOP was
calculated as the average of the 09:00 and 16:00 measurements
in the study eye at the particular visit. The a priori statistical
plan for the study included a subgroup analysis for patients
whose baseline IOP (at 09:00) on latanoprost was >20 mm Hg.
Categorical variables were analysed using the x
2 test or Fisher
exact test. Continuous variables were analysed using ANOVA
or ANCOVA. The percentage of patients with increased
biomicroscopic scores was compared between groups using the
Cochrane–Mantel–Haenszel row mean-score test.
Table 1 Patient characteristics at baseline
Bimatoprost
(n=131)
Travoprost
(n=135) p Value
Mean (SD) age in years, range 63.4 (12.3), 27 to 91 62.7 (12.4), 19 to 88 0.609
Sex 0.034
Female 81 (61.8%) 66 (48.9%)
Male 50 (38.2%) 69 (51.1%)
Race 0.572*
Black or African–American 36 (27.5%) 33 (24.4%)
White 75 (57.3%) 80 (59.3%)
Hispanic or Latino 16 (12.2%) 15 (11.1%)
Asian 2 (1.5%) 4 (3.0%)
American Indian or Alaska Native 0 (0.0%) 2 (1.5%)
Native Hawaiian or Pacific Islander 2 (1.5%) 0 (0.0%)
Multiracial 0 (0.0%) 1 (0.7%)
Iris colour 0.950{
Brown 82 (62.6%) 84 (62.2%)
Blue 30 (22.9%) 31 (23.0%)
Hazel 12 (9.2%) 16 (11.9%)
Green 7 (5.3%) 4 (3.0%)
Diagnosis 0.644
Ocular hypertension (OHT) 28 (21.4%) 29 (21.5%)
Primary open-angle glaucoma (POAG) or 101 (77.1%) 99 (73.3%)
pigmentary glaucoma
Chronic angle-closure glaucoma (CACG) 0 (0.0%) 1 (0.7%)
Mixed{ 1 (0.8%) 3 (2.2%)
Other1 1 (0.8%) 3 (2.2%)
Value shown in bold: p,0.05.
*p Value for black or African–American versus all other race categories.
{p Value for dark (brown) versus light (blue, hazel or green).
{One eye diagnosed as having OHT and the other with open-angle glaucoma.
1Pseudoexfoliative glaucoma or normal-tension glaucoma.
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0.05. Statistical analyses were performed using SAS version 8.2
(SAS Institute, Cary, North Carolina). The planned sample size
was 125 patients in each group, which provided 80% power to
detect a 1 mm Hg difference between groups, assuming a
common SD of 2.8 mm Hg.
RESULTS
Patient baseline characteristics and disposition
Two hundred and sixty-six patients with inadequate IOP
control on latanoprost monotherapy were enrolled in the study
and randomised to either bimatoprost or travoprost mono-
therapy. Patient characteristics at baseline are listed in table 1. A
larger percentage of patients in the travoprost group were male.
There were no other statistically significant differences in
demographics between treatment groups. Most patients were
diagnosed as having bilateral glaucoma associated with elevated
IOP.
Study completion rates were high in each group, and 259
patients (97.4%) completed the study (table 2).
IOP-lowering efficacy
Intraocular pressure data were available for 98.7% (1575/1596)
of planned measurements. At the latanoprost-treated baseline,
there were no significant differences between treatment groups
in mean IOP at individual time points (09:00 and 16:00) or in
mean (SD) diurnal IOP (bimatoprost: 19.1 (SD 2.8) mm Hg;
travoprost: 18.9 (2.7) mm Hg; p=0.473). After replacement of
latanoprost therapy with bimatoprost or travoprost therapy,
the mean IOP was significantly lower with bimatoprost than
with travoprost at the 09:00 time point at month 1 and the
16:00 time point at month 3 (table 3).
The mean reduction from baseline IOP on latanoprost was up
to 2.2 mm Hg (11.1%) with bimatoprost and up to 1.5 mm Hg
(7.7%) with travoprost at the 09:00 measurements and up to
2.0 mm Hg (10.8%) with bimatoprost and up to 1.2 mm Hg
(6.6%) with travoprost at the 16:00 measurements (table 4).
The mean diurnal IOP was significantly lower with bimato-
prost than with travoprost at both months 1 and 3 (fig 1).
Replacing latanoprost with travoprost led to a mean reduction
from baseline diurnal IOP of 1.2 (95% CI 0.8 to 1.6) mm Hg at
month 1 and 1.4 (95% CI 0.9 to 1.8) mm Hg at month 3, while
replacing latanoprost with bimatoprost led to significantly
larger mean decreases from baseline diurnal IOP of 1.9 (95% CI
1.6 to 2.3) mm Hg at month 1 and 2.1 (95% CI 1.7 to 2.5) mm
Hg at month 3 (table 4).
In the subgroup of patients whose baseline IOP on
latanoprost was ,20 mm Hg, the mean diurnal IOP was
significantly lower with bimatoprost than with travoprost at
both 1 and 3 months (fig 2A). At month 3, the mean reduction
from latanoprost-treated baseline diurnal IOP was 1.8 (95% CI
1.3 to 2.2) mm Hg (10.4%) with bimatoprost versus 0.5 mm
(95% CI 0.0 to 1.0) Hg (2.9%) with travoprost (p,0.001). In
contrast, there was no significant difference in efficacy between
bimatoprost and travoprost in the subgroup of patients whose
baseline IOP on latanoprost was >20 mm Hg (fig 2B). At
month 3, the mean reduction from latanoprost-treated baseline
diurnal IOP in these patients was 2.5 (95% CI 1.7 to 3.2) mm
Hg (11.8%) for bimatoprost and 2.5 (95% CI 1.8 to 3.2) mm Hg
(11.8%) for travoprost.
Overall, an additional reduction in diurnal IOP from
latanoprost-treated baseline of at least 15% was achieved at
both month 1 and month 3 by 22.0% of patients in the
bimatoprost group compared with 12.1% of patients in the
travoprost group (p=0.033). In subgroup analyses, at least a
15% reduction in diurnal IOP from latanoprost-treated baseline
was achieved at both month 1 and month 3 by 20.3% of
bimatoprost patients versus 8.2% of travoprost patients who
had baseline diurnal IOPs,20 mm Hg (p=0.053) and by 24.1%
of bimatoprost patients versus 16.9% of travoprost patients
who had baseline diurnal IOPs>20 mm Hg (p=0.368).
Safety and tolerability
Both bimatoprost and travoprost were well tolerated and
associated with a low incidence of adverse events. Only two
patients, both in the bimatoprost group, discontinued from the
study early because of adverse events (periorbital itching and
dryness; asthma exacerbation unrelated to treatment).
Treatment-related adverse events (table 5) were reported for
11 patients (8.4%) in the bimatoprost group and eight patients
(6.0%) in the travoprost group (p=0.485). None were
categorised as serious. Ocular or conjunctival hyperaemia was
reported as a treatment-related adverse event for 3.1% of
bimatoprost patients and 1.5% of travoprost patients
(p=0.445).
On biomicroscopy, conjunctival hyperaemia and punctate
keratitis were the only findings with >1-grade increases in
severity reported in at least 4% of patients in either treatment
Table 2 Patient disposition
Bimatoprost Travoprost
Patients randomised 131 (100.0%) 135 (100.0%)
Completed study 127 (96.9%) 132 (97.8%)
Discontinued 4 (3.1%) 3 (2.2%)
Reason for discontinuation
Adverse event* 2 (1.5%) 0 (0.0%)
Protocol violation 1 (0.8%) 1 (0.7%)
Lost to follow-up 0 (0.0%) 2 (1.5%)
Personal reason 1 (0.8%) 0 (0.0%)
*Adverse event could be related or unrelated to treatment.
Table 3 Mean intraocular pressure (IOP) at each hour and visit
Baseline Month 1 Month 3
09:00 16:00 09:00 16:00 09:00 16:00
Bimatoprost
Mean (SD) IOP, mm Hg 19.8 (2.9) 18.5 (3.1) 17.6 (2.8) 16.8 (2.8) 17.6 (3.3) 16.5 (3.2)
n 131 131 129 128 128 128
Travoprost
Mean (SD) IOP, mm Hg 19.5 (3.1) 18.2 (2.9) 18.3 (3.1) 17.0 (2.7) 18.1 (3.0) 17.0 (2.7)
n 135 135 133 133 132 132
p Value 0.530 0.492 0.004 0.162 0.058 0.047
Values shown in bold: p,0.05.
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one-grade, two-grade or three-grade increase in the severity of
conjunctival hyperaemia from baseline, respectively, were 8.4%,
2.3% and 0.8% in the bimatoprost group and 13.5%, 3.0% and
0.0% in the travoprost group. There were no significant
differences between treatment groups, and none of the patients
in the study discontinued due to conjunctival hyperaemia or
punctate keratitis.
There was no significant between-group difference in the
change from baseline visual acuity.
DISCUSSION
The primary goal of glaucoma treatment is to reduce IOP to the
target pressure using a minimal number of medications.
16 This
prospective, randomised study confirms previous reports
10 12–14
demonstrating that additional IOP lowering may be achieved by
switching patients who are inadequately controlled on latano-
prost to another PGA and reinforces the concept that changing
therapy within the PGA class should be considered prior to
adding a second medication if further IOP lowering is required.
17
Despite the fact that the mean diurnal IOP on latanoprost
was approximately 19 mm Hg at baseline in both treatment
groups, which is within the statistically normal range of IOPs,
patients still achieved additional IOP lowering after switching
to either bimatoprost or travoprost. The mean diurnal IOP was
significantly lower with bimatoprost than with travoprost at
both 1 and 3 months. It has been suggested that an adjunctive
medication should provide at least 15% additional IOP low-
ering.
17 In this study, 22% of patients consistently achieved at
least 15% additional IOP lowering after replacing latanoprost
with bimatoprost, that is, they had as much additional IOP
lowering as if they had successfully added a second medication
to latanoprost, yet they were able to maintain monotherapy.
Conjunctival hyperaemia, the most common side effect of the
PGAs, has typically been reported as an unsolicited adverse
event in 40% to 50% of patients treated with bimatoprost or
travoprost after washout of prior medications.
136In the present
study, a low percentage of patients had increased conjunctival
hyperaemia after switching from latanoprost (10% in each
treatment group at month 1). This study more closely replicates
clinical practice in that patients were switched directly from
latanoprost without undergoing a washout. In fact, there were
only four adverse event reports of treatment-related hyperaemia
in the bimatoprost group and two in the travoprost group.
More importantly, no patients discontinued using either
medication due to conjunctival hyperaemia. The tolerability
findings are consistent with prior reports in which patients were
systematically switched from latanoprost to another PGA,
11
illustrating that prior PGA exposure and a direct switch among
PGAs reduce the incidence and severity of hyperaemia
associated with bimatoprost or travoprost.
The decision of whether to switch medications or add
another medication can be difficult when patients’ IOPs are
relatively controlled (eg, less than 20 mm Hg) on monotherapy.
The results of the subgroup analysis indicate that replacing
latanoprost with bimatoprost is a viable option, even for these
patients. For patients whose baseline IOP on latanoprost was
less than 20 mm Hg, bimatoprost provided 1.8 mm Hg of
additional diurnal IOP lowering compared with the 0.5 mm Hg
provided by travoprost (p,0.001). In contrast, bimatoprost and
travoprost were similarly effective in patients whose baseline
IOP on latanoprost was 20 mm Hg or higher, each reducing
diurnal IOP by 2.5 mm Hg after 3 months of treatment.
Meta-analyses of data from parallel-group
8 and 24 h cross-
over
18 clinical studies have suggested that bimatoprost and
travoprost are the most effective medications available for IOP
lowering. In head-to-head studies comparing bimatoprost and
travoprost in treatment-naı ¨ve patients or patients washed out
of previous medications, bimatoprost has reduced IOP at least as
well or significantly better than travoprost.
19–22 These results are
consistent with the present study, which demonstrated a
substantial decrease in mean IOP when latanoprost was
Table 4 Mean decrease from baseline intraocular pressure (IOP)
Month 1 Month 3
09:00 16:00 Diurnal 09:00 16:00 Diurnal
Bimatoprost
Mean (SD) IOP reduction, mm Hg 2.2 (2.5) 1.7 (2.6) 1.9 (2.2) 2.2 (2.8) 2.0 (2.7) 2.1 (2.4)
Percentage reduction 11.1% 9.2% 9.9% 11.1% 10.8% 11.0%
n 129 128 129 128 128 128
Travoprost
Mean (SD) IOP reduction, mm Hg 1.2 (2.8) 1.2 (2.7) 1.2 (2.3) 1.5 (3.1) 1.2 (2.9) 1.4 (2.5)
Percentage reduction 6.2% 6.6% 6.3% 7.7% 6.6% 7.4%
n 133 133 133 132 132 132
p Value 0.004 0.162 0.009 0.058 0.047 0.024
Values shown in bold: p,0.05.
Figure 1 Mean diurnal intraocular pressure (IOP) in each treatment
group at latanoprost-treated baseline and after 1 and 3 months of
bimatoprost or travoprost replacement therapy. Error bars represent the
standard error of the mean. *p=0.009 versus travoprost;
+p=0.024
versus travoprost.
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mean IOP was significantly lower with bimatoprost than with
travoprost at half of the time points.
The difference in efficacy between bimatoprost and latano-
prost in the present study was similar in magnitude to that in
the comparison study reported by Noecker and associates,
6 yet
larger than the average difference of approximately 1 mm Hg
that has been reported.
78This discrepancy may be explained in
part by differences in study populations and study design, as
patients in previous studies were typically treatment-naı ¨ve or
washed out of previous medications rather than switched
directly between the PGAs. In the present study, all patients
were treated with latanoprost prior to randomisation to masked
treatment with bimatoprost or travoprost, potentially introdu-
cing an element of bias in the comparisons of latanoprost with
the other PGAs.
Interpretation of the results of switch studies is sometimes
limited by the possibility of an increase in compliance. A change
in compliance is unlikely to account for the IOP reduction
observed in the present study, however, as patients who were
screened were required to be run-in on latanoprost for an
additional 2 weeks prior to the baseline evaluations. The
present study was limited because tests of within-group
changes from baseline IOP were not included in the a priori
statistical plan for the study. However, posthoc analyses using
within-group t tests showed that the changes from baseline
diurnal IOP were statistically significant in both the bimato-
prost and travoprost groups (p,0.001). Of note, the reduction
in IOP was statistically significant for bimatoprost in patients
with baseline IOP,20 mm Hg or >20 mm Hg (p,0.001). In
contrast, in patients with baseline IOP,20 mm Hg who
switched to travoprost treatment, the change from baseline
IOP did not achieve statistical significance at 3 months
(p=0.187). As the inclusion criteria only required at least
30 days of latanoprost therapy without any further delineation
or stratification based on length of prior use, we are unable to
relate the duration of latanoprost treatment to outcomes in the
Figure 2 Mean diurnal intraocular pressure (IOP) at latanoprost-treated baseline and after 1 and 3 months of bimatoprost or travoprost replacement
therapy for patients with baseline IOP,20 mm Hg (A) and patients with baseline IOP>20 mm Hg (B). Error bars represent standard error of the mean.
*p=0.007 versus travoprost;
+p,0.001 versus travoprost.
Table 5 Treatment-related adverse events
Adverse event
No (%) of patients
Bimatoprost (n=131) Travoprost (n=133)
Eye pruritus 3 (2.3%) 1 (0.8%)
Conjunctival or ocular hyperaemia 4 (3.1%) 2 (1.5%)
Punctate keratitis 1 (0.8%) 2 (1.5%)
Eye irritation 2 (1.5%) 0 (0.0%)
Growth of eyelashes 2 (1.5%) 0 (0.0%)
Abnormal sensation in eye 1 (0.8%) 0 (0.0%)
Drug hypersensitivity 0 (0.0%) 1 (0.8%)
Dry skin 1 (0.8%) 0 (0.0%)
Foreign-body sensation 0 (0.0%) 1 (0.8%)
Hyperaemia (non-ocular) 0 (0.0%) 1 (0.8%)
Pruritus at instillation site 0 (0.0%) 1 (0.8%)
Skin pigmentation 1 (0.8%) 0 (0.0%)
Visual acuity reduced 0 (0.0%) 1 (0.8%)
Overall* 11 (8.4%) 8 (6.0%)
*Patients reporting any treatment-related adverse event.
Figure 3 Percentage of patients with at least a one-grade increase
from baseline in biomicroscopic conjunctival hyperaemia and corneal
punctate keratitis scores. Most patients in each group had none-to-trace
conjunctival hyperaemia and punctate keratitis on latanoprost baseline
(bimatoprost: 93%, 96%; travoprost: 88%, 95%, respectively).
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short-term study, and diurnal IOP was determined based on
only two time points over a period of time representing a typical
office day. Future studies of longer duration or using additional
time points will be needed to fully evaluate efficacy during long-
term treatment and over the course of a 24 h period.
In summary, switching therapy within the PGA class may
allow patients to reach lower pressures while maintaining
monotherapy. The results of this study have demonstrated that
when additional efficacy is needed, switching from latanoprost
monotherapy to bimatoprost may provide greater additional
IOP lowering than switching to travoprost. The rate of
increased hyperaemia is low in patients switched directly from
latanoprost to either bimatoprost or travoprost.
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